Clinical Trials Directory

Trials / Recruiting

RecruitingNCT06268717

GI Alpha-Gal Study

Understanding Gastrointestinal Alpha-Gal Syndrome: (GI Alpha-Gal Study)

Status
Recruiting
Phase
N/A
Study type
Interventional
Enrollment
30 (estimated)
Sponsor
University of North Carolina, Chapel Hill · Academic / Other
Sex
All
Age
18 Years – 99 Years
Healthy volunteers
Not accepted

Summary

This is a double-blind, crossover food challenge study using pork with and without α-gal in patients with a clinical diagnosis of gastrointestinal (GI)- α-gal allergy, and to investigate the pathophysiology underlying their symptoms.

Detailed description

Each participant will be randomized to undergo two double-blind food challenges with at least a 10-day washout period between the challenges. One food challenge will contain pork meat with alpha gal sugar; one challenge will contain pork meat without the alpha gal sugar. During the challenges, participants will drink lactulose and C13 mannitol dissolved in water. The principal investigator and clinical research coordinators will be blinded to the challenges during the course of the study. The metabolic kitchen and a delegated research staff member will be unblinded. On consenting patients, a transnasal upper endoscopy (TNE) will be performed on each challenge day, pre-challenge, at hour 0 and post-challenge, at hour 6. During the TNE, esophagus, stomach and small bowel samples will be collected. Gastrointestinal pathology samples will be evaluated for inflammatory cells and also biobanked for further messenger RNA (mRNA) sequencing studies. Blood and urine will be collected during each challenge. Samples will be transported to a lab and analyzed for tryptase, basophil activation, and lactulose/ mannitol levels.

Conditions

Interventions

TypeNameDescription
OTHERGround pork containing alpha-gal150 grams of cooked, ground pork meat containing alpha-gal sugar eaten once
OTHERPork meat not containing alpha-gal150 grams of cooked, ground pork meat not containing alpha-gal sugar

Timeline

Start date
2023-10-17
Primary completion
2026-06-02
Completion
2026-06-02
First posted
2024-02-20
Last updated
2025-10-20

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT06268717. Inclusion in this directory is not an endorsement.